Summary
Retatrutide is a synthetic peptide developed by Eli Lilly that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is an investigational drug in late-stage clinical trials for obesity and type 2 diabetes and is not yet licensed anywhere. Its long duration of action comes from a fatty-acid chain attached to the peptide.
What it targets
Retatrutide activates the GLP-1, GIP and glucagon receptors, which between them influence appetite, insulin release and energy expenditure. In a phase 2 trial substudy in adults with type 2 diabetes, it reduced total body fat mass measured by DXA compared with placebo and dulaglutide over 36 weeks, with gastrointestinal effects the most common adverse events. In diet-induced obese rats, combining it with cagrilintide lowered body weight and food intake more than either drug alone. A mouse study presented as a conference abstract reported reduced pancreatic tumour growth at a dose that did not cause weight loss; that finding has not been published as a full paper.
Clinical Research
Suppliers stocking Retatrutide
10 of the 30 listed suppliers. Each row opens its full listing.